AKT1 and esophageal squamous cell carcinoma: Addressing these mechanistic and translational gaps could elevate PTGDS from a promising prognostic marker to an actionable biomarker that guides targeted modulation of the PI3K/AKT axis and enhances immunotherapeutic effectiveness in ESCC.